Article Text
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMed
Context
There is a biological and epidemiological evidence to suggest that high oestrogen levels retard the progression of atherogenesis, reducing the risk of myocardial infarction. Whether such an effect is evident following a first myocardial infarction is unclear. A randomised controlled trial was carried out to investigate. Following completion of the trial the authors continued the follow-up in order to evaluate the long-term safety of unopposed oestrogen.
Methods
Women aged 50–79 years who sustained a first myocardial infarction (MI) and who had not used hormone replacement therapy in the preceding year were randomised …
Footnotes
-
Competing interests SS has in the past consulted, and presently consults with, Bayer Schering and with other manufacturers of female hormones.
-
Provenance and peer review Not commissioned; internally peer reviewed.